Lantern Pharma annual stock-based compensation
2021
2022
2023
2024
2025
Lantern Pharma Stock-Based Compensation Growth & History (LTRN)
Lantern Pharma's stock-based compensation was $651,000 for fiscal 2025.
View full Lantern Pharma company overviewLantern Pharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $651,000 | −$1,000 | −0.15% |
| 2024 | 2024-12-31 | $652,000 | −$365,000 | −35.89% |
| 2023 | 2023-12-31 | $1.0M | −$170,745 | −14.38% |
| 2022 | 2022-12-31 | $1.2M | $226,200 | +23.52% |
| 2021 | 2021-12-31 | $961,545 | — | — |
Lantern Pharma quarterly stock-based compensation
Q2.19
Q3.19
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $285,260 | $124,634 | +77.59% |
| Q1 2026 | 2026-03-31 | $262,915 | $115,165 | +77.95% |
| Q4 2025 | 2025-12-31 | $198,939 | −$5,667 | −2.77% |
| Q3 2025 | 2025-09-30 | $143,685 | −$35,481 | −19.80% |
| Q2 2025 | 2025-06-30 | $160,626 | $26,455 | +19.72% |
| Q1 2025 | 2025-03-31 | $147,750 | $13,693 | +10.21% |
| Q4 2024 | 2024-12-31 | $204,606 | $104,281 | +103.94% |
| Q3 2024 | 2024-09-30 | $179,166 | −$11,589 | −6.08% |
| Q2 2024 | 2024-06-30 | $134,171 | −$258,219 | −65.81% |
| Q1 2024 | 2024-03-31 | $134,057 | −$199,473 | −59.81% |
| Q4 2023 | 2023-12-31 | $100,325 | −$229,770 | −69.61% |
| Q3 2023 | 2023-09-30 | $190,755 | −$110,358 | −36.65% |
| Q2 2023 | 2023-06-30 | $392,390 | $102,857 | +35.53% |
| Q1 2023 | 2023-03-31 | $333,530 | $66,526 | +24.92% |
| Q4 2022 | 2022-12-31 | $330,095 | $84,166 | +34.22% |
| Q3 2022 | 2022-09-30 | $301,113 | $76,700 | +34.18% |
| Q2 2022 | 2022-06-30 | $289,533 | $43,849 | +17.85% |
| Q1 2022 | 2022-03-31 | $267,004 | $21,485 | +8.75% |
| Q4 2021 | 2021-12-31 | $245,929 | — | — |
| Q3 2021 | 2021-09-30 | $224,413 | $181,413 | +421.89% |
| Q2 2021 | 2021-06-30 | $245,684 | $140,684 | +133.98% |
| Q1 2021 | 2021-03-31 | $245,519 | — | — |
| Q3 2020 | 2020-09-30 | $43,000 | $11,000 | +34.38% |
| Q2 2020 | 2020-06-30 | $105,000 | $99,000 | +1650.00% |
| Q3 2019 | 2019-09-30 | $32,000 | — | — |
| Q2 2019 | 2019-06-30 | $6,000 | — | — |
Lantern Pharma stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Lantern Pharma's stock-based compensation decreased from $961,545 to $651,000, a change of −$310,545. The latest reported quarter, Q2 2026, shows $285,260.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lantern Pharma source filings ↗